Notice of Results
Summary by AI BETAClose X
22 May 2026
GENinCode Plc
("GENinCode" or the "Company")
Notice of results
Analyst and investor briefing
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, announces that it will release its audited final results for the year ended 31 December 2025 on Monday, 8 June 2026.
Analyst briefing
A briefing open to equity research analysts will take place on Monday 8 June 2026 at 09.30am BST. To register and for more details please contact Walbrook PR on genincode@walbrookpr.com.
Investor presentation
Matthew Walls, Chief Executive Officer, and Paul Foulger, Chief Financial Officer, will provide a live presentation relating to the results via the Investor Meet Company platform on Wednesday, 10 June at 11am BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet GENinCode here. Investors who already follow GENinCode on the Investor Meet Company platform will automatically be invited.
For more information visit www.genincode.com
Enquiries:
|
GENinCode Plc |
www.genincode.com or via Walbrook PR |
|
|
Matthew Walls, CEO |
|
|
|
Paul Foulger, CFO |
||
|
|
|
|
|
Cavendish Capital Markets Limited |
Tel: +44 (0)20 7397 8900 |
|
|
Giles Balleny / Trisyia Jamaludin (Corporate Finance) |
||
|
Harriet Ward (Corporate Broking) |
||
|
Nigel Birks (Specialist Sales) |
||
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or genincode@walbrookpr.com |
|
|
Anna Dunphy |
|
|
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict cardiovascular disease.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 14 minutes ago SThree
- 14 minutes ago Premier Foods
- 57 minutes ago Oxford Biomedica
- 1 hour ago Marks & Spencer Group
- 1 hour ago Centrica